Drugs / XG-104
last change Feb 2015 re-read 3 minutes ago

XG-104

Developed for
dry eye syndrome
Investigated by
Xigen SA

Trials 1

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02235259 Sep 2014 → Feb 2015 dry eye syndrome Xigen SA Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as XG-104 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02235259 ↗